Cytokinetics CYTK 深 滬
等待開盤 08-21 09:30:00 美东时间
77.18
-0.560
-0.72%
華盛通- 最 高77.62
- 今 開77.36
- 成交量 165.17万股
- 最 低 76.14
- 昨 收 77.74
- 總市值 107.30亿
- 52周最高 88.31
- 市盈率 靜 --
- 換手率 1.19%
- 52周最低 44.91
- 委 比 -33.82%
- 總股本 1.39亿
- 歷史最高 110.25
- 量 比 1.01
- 振 幅 1.90%
- 歷史最低 0.57
- 每 手 1
- 風險率 10.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics granted stock options and RSUs to 12 new employees as inducements to employment. The RSUs vest over 3 years, with 40%, 40%, and 20% vesting annually. Stock options, priced at $74.13, vest over 4 years with monthly installments after the first year. Both awards are subject to continued employment and comply with Nasdaq rules. Cytokinetics, a cardiovascular biopharmaceutical company, focuses on developing treatments for heart condition...
08-18 20:00
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Bristol gains accelerated approval of iberdomide for multiple myeloma
The US FDA granted accelerated approval to Bristol Myers Squibb's (BMY) Zenbexus (iberdomide), in combination with Johnson & Johnson's (JNJ) Darzalex (daratumumab), hyaluronidase-fihj and dexamethason...
08-14 05:29
Cytokinetics sues Bristol-Myers to avoid patent dispute
Cytokinetics (CYTK) on Thursday disclosed a lawsuit against Bristol-Myers Squibb (BMY) and its 2020 buyout, MyoKardia, to avoid a potential patent infringement case related to its heart disease therap...
08-13 22:49
Cytokinetics Files Delaware U.S. District Court Claim Against Bristol-Myers Squibb And MyoKardia Seeking Judgment That CYTK Isn't Infringing U.S. Patent No. 12,616,697 And That The ’697 Patent Claims Are Invalid
In the complaint, the Company requests, among other things: a judgment declaring that the Company does not infringe and has not infringed any valid claim of the ’697 patent; a judgment declaring that the claims of the ’697 patent are invalid; a judgment preliminarily and permanently enjoining the de...
08-13 21:35
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Needham Maintains Buy on Cytokinetics, Raises Price Target to $112
Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $102 to $112.
08-07 21:28
财报速睇 | Cytokinetics 2026财年Q2营收0.29亿美元，同比下降56.7%；归母净利润亏损1.99亿美元，同比亏损扩大48.5%
华盛资讯8月7日讯，Cytokinetics公布2026财年Q2业绩，公司Q2营收0.29亿美元，同比下降56.7%，归母净利润亏损1.99亿美元，同比亏损扩大48.5%。
08-07 04:34
Opus, Cytokinetics, Albertsons, Weatherford, Paysign Shock
Insiders have been trading these 5 stocks: (($IRD)), (($CYTK)), (($ACI)), (($WF...
08-01 21:01
